MXiPr

Pre-existing hypertension, Coronary artery disease, Arrhythmias, Heart failure

NMDA antagonists including ketamine produce dose-dependent sympathomimetic cardiovascular effects — tachycardia and hypertension — via central sympathetic stimulation. No cardiovascular measurements specific to MXiPr have been published. Individuals with pre-existing cardiac conditions face increased risk from these hemodynamic changes.

Concurrent opioid use, Concurrent benzodiazepine use, Concurrent alcohol use, Concurrent GHB use

Concurrent use of MXiPr with CNS depressants (opioids, benzodiazepines, alcohol, GHB, barbiturates) produces additive respiratory depression and CNS depression that may be life-threatening. Fatal cases involving structurally related arylcyclohexylamines have occurred in polydrug contexts — the fatal N-ethyldeschloroketamine case (Theofel et al. 2019) involved co-presence of morphine, oxycodone, and other compounds.

Epilepsy, Lowered seizure threshold, History of seizures

User reports describe seizures occurring at very high doses of MXiPr. No case reports in published literature confirm this for MXiPr specifically, though NMDA antagonists as a class can affect seizure threshold. Individuals with epilepsy or lowered seizure threshold face increased risk.

Schizophrenia, Schizoaffective disorder, History of psychosis

Individuals with a personal history of psychotic disorders should avoid all NMDA receptor antagonists including MXiPr. NMDA antagonism produces psychotomimetic effects that can precipitate acute psychotic episodes or exacerbate existing psychotic illness. This is a class-established contraindication from ketamine and PCP research.

Liver disease, Hepatic insufficiency, Cirrhosis

MXiPr undergoes extensive hepatic metabolism as demonstrated by Frankenfeld et al. (2024) in rat and human liver microsome studies. Impaired hepatic function may slow clearance of MXiPr and its metabolites, prolonging exposure and increasing the risk of adverse effects. This is supported by substance-specific metabolic data, though human pharmacokinetic parameters remain uncharacterized.

Bladder disease, Urinary tract disease, Interstitial cystitis

Chronic ketamine and MXE administration has been associated with bladder inflammation, fibrosis, and lower urinary tract symptoms. Whether MXiPr carries this risk is unknown — no human clinical data or animal histology studies for MXiPr have been published. Individuals with pre-existing urological conditions may be at heightened risk if this class effect applies.

Pregnancy, Breastfeeding

No reproductive toxicity data exist for MXiPr. NMDA receptors are critical for neurodevelopment, and NMDA antagonist exposure during pregnancy carries theoretical teratogenic risk. The compound's metabolites and their potential transfer to breast milk have not been studied.

Concurrent MAOI therapy, Within 14 days of MAOI discontinuation

If MXiPr shares the serotonin transporter affinity demonstrated for its parent compound MXE, concurrent use with MAOIs poses serotonin syndrome risk. SERT activity has not been confirmed for MXiPr — this contraindication is inferred from structural analogy to MXE. Given the potentially fatal nature of serotonin syndrome, this is classified as absolute despite low confidence in the underlying SERT interaction.